Loading...

OTC Markets

Totals

Securities

12,441

Dollar Vol

$4.6B

Share Vol

4.1B

Trades

521,491

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

Market Activity
Stock
ADXS
Company Profile

ADXS
Ayala Pharmaceuticals, Inc.

Common Stock

9 Deer Park Drive

Suite K-1

Monmouth Junction, NJ 08852

ayalapharma.com

+1 (609) 452-9813

ir@ayalapharma.com

Last Verified 07/2024

Business Description

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic ...

Financial Reporting

Reporting Status

Dark: Alternative Reporting Standard

Audited Financials

Audited

Latest Report

12/31/2023

CIK

0001100397

Fiscal Year End

12/31

Company Officers & Contacts

Kenneth A. Berlin

CEO, Interim CFO

Igor Gitelman

Other

Oren Elmaliah

Other

Justin W. Chairman

Legal Counsel

Board of Directors

David Sidransky

Chairman, Independent Director, Compensation Committee Member, Nominating Committee Member

Ronie A. Appel

Independent Director, Audit Committee Member, Nominating Committee Member

Kenneth A. Berlin

CEO, Interim CFO

Vered Bisker-Leib

Independent Director, Audit Committee Member

Robert Spiegel M.D. F.A.C.P

Murray A. Goldberg

Independent Director, Audit Committee Member

Bridget Martell, M.D.

Pini Orbach, Ph.D.

Yuvall Cabilly, Ph.D.

Other Company Insiders

N/A N/A

AMOON GENERAL PARTNER LTD.

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.

Service Providers

Accounting/Auditing Firm

Kost Forer Gabbay & Kasierer

144 MenachemBegin Road,

Building ATel-Aviv 6492102

Tel-Aviv 67067

Israel

Securities Counsel

Morgan Lewis - Washington, DC (USA)

1111 Pennsylvania Avenue, NW

Washington, DC 20004-2541

Profile Data

SIC - Industry Classification

2834 - Pharmaceutical preparations

Incorporation Information

DE, US, 2002

Employees

21 as of 12/31/2023

Shell

Products and Services

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.

Company Facilities

9 Deer Park Drive, Suite K-1 Monmouth Junction, NJ 08852

Company Notes

Formerly=Advaxis, Inc. until 6-2023

Note=1-31-05 company is in the development stage